Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bio-Path Holdings, Inc. (NASDAQ: BPTH).

Full DD Report for BPTH

You must become a subscriber to view this report.


Recent News from (NASDAQ: BPTH)

Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference
HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced today announced that ...
Source: GlobeNewswire
Date: August, 29 2018 08:00
Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia
HOUSTON, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it has commenced Stag...
Source: GlobeNewswire
Date: August, 27 2018 07:30
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
HOUSTON, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jas...
Source: GlobeNewswire
Date: August, 16 2018 10:26
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2018 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (BPTH) Q2 2018 Earnings Conference Call August 15, 2018 8:30 AM ET Executives Will O’Connor – Stern Investor Relations Peter Nielsen – President and Chief Executive Officer Anthony Price – Vice President-Finance and Accounting ...
Source: SeekingAlpha
Date: August, 15 2018 12:46
Bio-Path Q2 net loss improves in Q2
Bio-Path ( BPTH ) Q2 results : Revenues: $0; Net Loss: ($1.7M) (+15.0%); Loss Per Share: ($0.15) (+51.6%); CF Flow Ops: ($3.4M) (+19.0%). More news on: Bio-Path Holdings, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 15 2018 07:22
Bio-Path Holdings Reports Second Quarter 2018 Financial Results
HOUSTON, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results ...
Source: GlobeNewswire
Date: August, 15 2018 07:00
Bio-Path reports Q2 results
Bio-Path (NASDAQ: BPTH ): Q2 EPS of -$0.15 More news on: Bio-Path Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 15 2018 06:26
Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018
HOUSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a li...
Source: GlobeNewswire
Date: August, 08 2018 09:15
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2018 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (BPTH) Q1 2018 Earnings Conference Call April 16, 2018 8:30 PM ET Executives Will O’Connor – Investor Relations Peter Nielsen – President and Chief Executive Officer Anthony Price – Vice President-Finance and Accounting Analy...
Source: SeekingAlpha
Date: May, 16 2018 14:16

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.260.25910.270.2349,998
2018-12-120.2820.24280.2820.21234,083
2018-12-110.2950.28540.2950.280199,014
2018-12-100.2930.29310.30880.293108,321
2018-12-070.31870.30950.370.2735149,959

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-139151,01590.1478Short
2018-12-121,86241,3584.5022Cover
2018-12-112,58820,52812.6072Cover
2018-12-1021,27323,57890.2239Short
2018-12-0711,04039,71027.8016Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BPTH.


About Bio-Path Holdings, Inc. (NASDAQ: BPTH)

Logo for Bio-Path Holdings, Inc. (NASDAQ: BPTH)

Bio Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Currently in Phase human trial.

 

Contact Information

 

 

Current Management

  • Peter Nielsen / CEO, CFO, COO
  • Peter Nielsen / Chairman
  • Michael J. Garrison /
  • Gillian IversRead /
  • Douglas P. Morris /

Current Share Structure

  • Market Cap: $19,518,575 - 05/14/2018
  • Issue and Outstanding: 11,340,756 - 03/22/2018

 


Recent Filings from (NASDAQ: BPTH)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018

 

 


Daily Technical Chart for (NASDAQ: BPTH)

Daily Technical Chart for (NASDAQ: BPTH)


Stay tuned for daily updates and more on (NASDAQ: BPTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BPTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BPTH and does not buy, sell, or trade any shares of BPTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/